期刊文献+

奥拉帕利不同晶型的制备、表征与稳定性研究

Preparation,Characterization and Stability of Different Crystal Forms of Olaparib
下载PDF
导出
摘要 制备奥拉帕利的6种晶型,研究其相对稳定性.采用X-射线粉末衍射分析、热分析、衰减全反射傅里叶红外光谱与拉曼光谱等多种分析检测技术对奥拉帕利6种晶型进行了固相表征,并通过高温转晶实验和溶剂介导实验研究晶型间的相对稳定性.奥拉帕利6种晶型中1种为水合物晶型H,2种为无水晶型A和L,3种为异质同晶溶剂化物,6种晶型的红外表征数据存在明显差异,可以用于6种晶型的鉴别及生产过程中的晶型控制.X-射线粉末衍射法、差示扫描量热法和拉曼光谱法在晶型A、H与L这3种晶型间存在较为明显的差异,可以用于这3种晶型的鉴别及生产过程中的晶型控制.无溶剂晶型间的稳定性关系为晶型A>晶型L,晶型A为热力学稳定晶型. Six crystal forms of olaparib were prepared and their relative stability was studied.First of all,the forms were characterized by X-ray powder diffraction,thermal analysis,attenuated total refraction infrared spectroscopy and Raman spectroscopy.Then,their relative stability was determined through high-temperature phase transformation and solvent-mediated transformation.Among these Six crystal forms,Form H is a hydrate,Form A and L are anhydrous,and the other three crystals are heteromorphic solvates.Also,there are obvious differences in the infrared spectroscopy data between the six solid forms,which can be used for the identification or polymorph control in the production process.There exist obvious differences in X-ray powder diffraction,thermal analysis or Raman spectorscopy in A,H and L.Furthermore,Form A,L and H can also be identified and controlled by X-ray powder diffraction,thermal analysis or Raman spectroscopy.In addition,the stability relationship is Form A>Form L for solvent-free Forms,that is to say,Form A is the most thermodynamic stable form.
作者 李宏名 胡瑞馨 郑维江 张娇 LI Hongming;HU Ruixin;ZHENG Weijiang;ZHANG Jiao(College Continuing Education,Wuhan Polytechnic University,Wuhan 430023,China;Sinopharm Chuankang Pharmaceutical Co.,Ltd.,Chengdu 611731,China;College of Horticulture,Sichuan Agricultural University,Chengdu 611130,China;Sichuan Kelun Pharmaceutical Research Institute Co.,Ltd.,Chengdu 611138,China)
出处 《成都大学学报(自然科学版)》 2023年第4期342-347,共6页 Journal of Chengdu University(Natural Science Edition)
基金 国家“重大新药创制”科技重大专项资助项目(2012ZX092021-013) 成都市高新区重点科技创新计划资助项目(15DFZD023)。
关键词 奥拉帕利 多晶型 异质同晶溶剂化物 稳定性 olaparib polymorph isomorphism solvate stability
  • 相关文献

参考文献6

二级参考文献53

  • 1王哲清.药物多晶型与有效性[J].中国医药工业杂志,2005,36(7):442-446. 被引量:22
  • 2吴霞,易学文.药物多晶型对药效及其理化性质影响的研究[J].四川理工学院学报(自然科学版),2007,20(3):48-50. 被引量:10
  • 3SIEGELR, MA J, ZOU Z, et al. Cancer statistics[J]. CA Cancer J Clin, 2014,64( 1 ) :9 - 29.
  • 4AstraZeneca AB. Lynparza 50 mg hard capsules: EU summary ofproduct characteristics[ EB/OL], 2014. http ://www. ema. euro- pa. eu/ema.
  • 5AstraZeneca Pharmaceuticals LP. LynparzaTM (olaparib) cap- sules, for oral use : US prescribing information ~ EB/OL ]. 2014. http ://www. accessdata, fda. gov/scripts/cder/drugsatfda/index. cfm.
  • 6BRYANT HE, SCHULTZ N, THOMAS HD, et al. Specific kill- ing BRCA2-deficient tumours with inhibitors of poly ( ADP-ri- bose) polymerase [ J ]. Nature, 2005, 434 ( 7035 ) : 913 - 917.
  • 7BURGESS M, PUHALLA S. BRCA l/2-mutation retated and sporadic breast and ovarian cancers: more alike than different [J]. Front Oncol, 2014, 4:19.
  • 8EMMA DD. Olararib: First global approval[ J]. Drugs, 2015, 75(2) :231 -240.
  • 9LEDERMANN J, HARTER P, GOURLEY C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer [J]. NEnglJMed, 2012, 366(15):1382-1392.
  • 10MATULONIS UA, HARTER P, GOURLEY C, et al. Analysis of intermediate clinical endpoints from a phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ abstract no. 132 ~ I J]. Gyne- col Oneo1,2014,133 ( Suppl 1 ) : $54 - $55.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部